Ribosome and aminoacyl-tRNA synthetase

The ribosome and aminoacyl-tRNA synthetases (aaRSs) are the fundamental components of the cellular translation machinery. The ribosome is a complex ribonucleoprotein assembly that facilitates the translation of genetic information from mRNA into proteins (Wilson, 2014). Aminoacyl-tRNA synthetases are a family of enzymes responsible for the precise attachment of amino acids to their cognate tRNA molecules, a process known as charging (Pham et al., 2014). These entities are critical for the survival of all organisms, making them highly effective targets for antimicrobial agents. Most ribosome-targeting drugs are antibiotics, such as macrolides and aminoglycosides, that exploit structural differences between prokaryotic and eukaryotic ribosomes to achieve selective toxicity (Wilson, 2014). aaRS inhibitors, such as mupirocin and tavaborole, target specific bacterial or fungal enzymes to halt protein production (PubChem; FDA). Beyond infectious diseases, these targets are increasingly relevant in oncology, as cancer cells often upregulate protein synthesis machinery to support rapid proliferation (Pham et al., 2014). Additionally, certain aaRSs are involved in autoimmune conditions, where the body produces antibodies against these enzymes, as seen in anti-synthetase syndrome. Therapeutic challenges include the potential for mitochondrial toxicity due to the evolutionary similarity between bacterial and mitochondrial ribosomes (Wilson, 2014). Overall, this machinery represents one of the most successful and diverse classes of drug targets in clinical medicine.

Other names

Protein synthesis machineryTranslation apparatusaaRSRibosomal subunitsAminoacyl-tRNA ligase

Inhibition of protein synthesis by either blocking the charging of tRNA with amino acids (aaRS inhibition) or by binding to ribosomal subunits (30S or 50S) to interfere with mRNA decoding, peptide bond formation, or translocation (Wilson, 2014; Pham et al., 2014).